Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05657496 · ClinicalTrials.gov registry record · Phase 1
Biological Response to Platelet-rich Plasma and Corticosteroid Injections
A Phase 1 study, sponsored by University of Missouri-Columbia.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT05657496: Clinical Trial Phase 1 study, sponsored by University of Missouri-Columbia.
NCT05657496 is a Phase 1 study that was terminated before completion, run by University of Missouri-Columbia. The registered enrollment target is 23 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05657496, a Phase 1 study, was terminated before completion, sponsored by University of Missouri-Columbia.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The goal is to determine how two different injections, corticosteroid and platelet-rich plasma, are used to treat patients with knee osteoarthritis may affect a patient's pain and function. Secondarily, the investigators are also interested in knowing how the two types of injections that will be given may affect what happens in the joint cartilage. The participants will receive one of the two injection types at the initial visit. There will be surveys to complete (around 10 questions) about the participants' knee and overall function. The investigators will ask these same questions on seven separate occasions. In addition, the investigators will ask the participants to provide blood and urine samples at our clinic before the first knee injection and before any other injection that is needed over the course of the study. During the injections, synovial fluid will be aspirated from the participants' knee at the initial visit and the one month visit. If the participants decide to go to surgery to help relieve the pain from osteoarthritis at any point during the study, the investigators will collect the material from the participants' knee that would be normally discarded as medical waste. Previous studies have indicated that concentrations of inflammatory and degradative biomarkers in patient serum, urine, and synovial fluid may provide insight into OA pathophysiology. To our knowledge, no study has been performed to assess the impact of intra-articular PRP injection upon fluid concentrations of a comprehensive panel of proposed OA-related biomarkers. In this study, the investigators will evaluate the impact of intra-articular PRP injection upon markers of cartilage matrix turnover, inflammatory mediators, degradative enzymes, inhibitors of degradative enzymes, and markers of bone metabolism in serum, urine, and synovial fluid of knee OA patients.
Primary Outcome
MCP-1 is a proinflammatory chemokine that recruits monocytes to sites of injury or inflammation. It plays a key role in the immune response and has been implicated in various chronic inflammatory and cardiovascular diseases.
Interventions
- DRUG Triamcinolone Acetonide 40 mg/ml Inj, Susp
- BIOLOGICAL Platelet-rich plasma Inj
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2022-12-28 |
| Est. Completion | 2025-06-18 |
| Phase | Phase 1 |
Why NCT05657496 stopped before completion
NCT05657496 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 2 interventions - of which Triamcinolone Acetonide 40 mg/ml Inj, Susp is the first listed.
NCT05657496 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05657496 about?
NCT05657496 is a clinical study titled "Biological Response to Platelet-rich Plasma and Corticosteroid Injections". The goal is to determine how two different injections, corticosteroid and platelet-rich plasma, are used to treat patients with knee osteoarthritis may affect a patient's pain and function. Secondarily, the investigators are also interested in knowing how the two types of injections that will be giv...
What is the current status of trial NCT05657496?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2022-12-28. Estimated completion is 2025-06-18.
What interventions are being tested in trial NCT05657496?
The interventions under investigation include: Triamcinolone Acetonide 40 mg/ml Inj, Susp (DRUG), Platelet-rich plasma Inj (BIOLOGICAL).
Who is sponsoring clinical trial NCT05657496?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05657496's enrollment target sits among peer trials
23 1596th of 2000 higher than 400 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI